Journal of Pediatric and Adolescent Gynecology
Volume 19, Issue 2 , Pages 81-87 , April 2006

Assessment of Knowledge and Attitudes of Young Uninsured Women toward Human Papillomavirus Vaccination and Clinical Trials

  • Edson Duarte Moreira Jr., MD, PhD

      Affiliations

    • Núcleo de Apoio à Pesquisa, Associação Obras Sociais Irmã Dulce, Salvador, Bahia, Brazil
    • Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil
    • Diretoria Científica, Hospital São Rafael, Salvador, Bahia, Brazil
    • Corresponding Author InformationAddress correspondence to: Edson Duarte Moreira Jr, MD, PhD, Rua Waldemar Falcão 121, Salvador, Bahia, Brazil, CEP 40.295-001
    • ,
  • Bruno Gusmão de Oliveira

      Affiliations

    • Núcleo de Apoio à Pesquisa, Associação Obras Sociais Irmã Dulce, Salvador, Bahia, Brazil
    • Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil
    • ,
  • Raimundo Celestino Silva Neves

      Affiliations

    • Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil
    • ,
  • Sandra Costa

      Affiliations

    • Laboratórios Merck, Sharp & Dohme, São Paulo, Brazil
    • ,
  • Gisela Karic, RN

      Affiliations

    • Laboratórios Merck, Sharp & Dohme, São Paulo, Brazil
    • ,
  • José Otávio Costa Filho, MD

      Affiliations

    • Laboratórios Merck, Sharp & Dohme, São Paulo, Brazil

References 

  1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3
  2. Moscicki AB. Human papillomavirus infection in adolescents. Pediatr Clin North Am. 1999;46:783
  3. Dillner J, Meijer CJ, von Krogh G, Horenblas S. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl. 2000;194
  4. Franceschi S, Castellsague X, Dal Maso L, et al. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer. 2002;86:705
  5. Villa LL. Human papillomaviruses and cervical cancer. Adv Cancer Res. 1997;71:321
  6. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131
  7. Ho GY, Palan PR, Basu J, et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer. 1998;78:594
  8. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis. 1998;25:243
  9. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20
  10. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277
  11. McNeil C. HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst. 1997;89:280
  12. Hines JF, Ghim SJ, Jenson AB. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol. 1998;10:15
  13. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271
  14. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553
  15. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirology. 1996;39:54
  16. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis. 1999;179:612
  17. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1523;1996:347
  18. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 1645;2002:347
  19. Zimet GD, Fortenberry JD, Fife KH, et al. Acceptability of genital herpes immunization. The role of health beliefs and health behaviors. Sex Transm Dis. 1997;24:555
  20. Zimet GD, Mays RM, Winston Y, et al. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000;9:47
  21. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, et al. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001;32:243
  22. Bodenheimer HC, Fulton JP, Kramer PD. Acceptance of hepatitis B vaccine among hospital workers. Am J Public Health. 1986;76:252
  23. Liau A, Zimet GD, Fortenberry JD. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis. 1998;25:76
  24. Lambert EC. College students' knowledge of human papillomavirus and effectiveness of a brief educational intervention. J Am Board Fam Pract. 2001;14:178
  25. Yacobi E, Tennant C, Ferrante J, et al. University students' knowledge and awareness of HPV. Prev Med. 1999;28:535
  26. Ramirez JE, Ramos DM, Clayton L, et al. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health. 1997;6:113
  27. Rosenthal SL, Kottenhahn RK, Biro FM, et al. Hepatitis B vaccine acceptance among adolescents and their parents. J Adolesc Health. 1995;17:248
  28. Hoover DR, Carfioli B, Moench EA. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int. 2000;21:375–391

PII: S1083-3188(06)00012-X

doi: 10.1016/j.jpag.2006.01.003

Journal of Pediatric and Adolescent Gynecology
Volume 19, Issue 2 , Pages 81-87 , April 2006

Article Tools

* Image Usage & Resolution